Proteus mirabilis is an important pathogen, being one of the most common enterobacterial species isolated from both community-acquired and health-careassociated infections (Adler et al., 2008; Bret et al., 1998; Endimiani et al., 2005) . In addition to extended-spectrum blactamases (ESBLs), acquired AmpC-type b-lactamases represent an important mechanism of resistance to extendedspectrum cephalosporins in P. mirabilis and are emerging in several European countries including France, Poland, Italy and Spain (Decre et al., 2002; Literacka et al., 2004; Luzzaro et al., 2009; Mata et al., 2010) .
While a standard methodology for detection and reporting ESBL-producing isolates has been endorsed by the Clinical and Laboratory Standards Institute (CLSI, 2008) and other Institutions (e.g. British Society for Antimicrobial Chemotherapy) (http://www.bsac.org.uk), no standard method has yet been officially endorsed for the laboratory detection of AmpC-producing organisms, nor have recommendations been issued for interpretation and reporting of the results of in vitro susceptibility assays with these organisms.
The present study evaluated the performance, using a large collection of P. mirabilis clinical isolates, of a new, simple and practical Double Synergy Differential Test (DSDT) that couples the detection of AmpC-type enzymes by means of a combo-disc approach using boronic acid as an enzyme inhibitor with that of ESBLs by means of a conventional combo-disc approach using clavulanic acid. The DSDT was performed as follows. The surface of a Mueller-Hinton agar plate (diameter 9 cm; BBL) was evenly inoculated using a cotton swab with a McFarland 0.5 bacterial suspension in normal saline, prepared from an overnight culture. After inoculation, three sets of discs were placed onto the medium. One set included a cefotaxime (CTX) (30 mg) and a ceftazidime (CAZ) (30 mg) disc; the second set included a cefotaxime plus clavulanate (CTX-CLA) and a ceftazidime plus clavulanate (CAZ-CLA) disc; the third set included a cefotaxime plus boronic acid (CTX-BA) and a ceftazidime plus boronic acid (CAZ-BA) disc. Results were recorded after incubation of the plates at 35 u C for 16-20 h. For ESBL detection, results were interpreted as recommended by the CLSI, i.e. ¢5 mm increase of inhibition zone diameter around CTX and/or CAZ disks was tentatively adopted as a cut-off value for synergy with boronate indicating AmpC production. The discs containing boronic acid were prepared by adding to each antibiotic-containing disc, immediately after deposition on plate, 10 ml of a 60 mg ml 21 solution of
The presence of ESBL and AmpC-type genes was screened by colony-blot hybridization using DNA probes for bla TEM -, bla SHV -, bla PER -, bla CTX-M -and bla CMY -type genes, essentially as described by Srinivasan et al. (2007 With AmpC-producing organisms, the enlargement of the inhibition zone in the presence of boronate varied between 6.2 and 12.9 mm (mean 9.5 mm). With AmpC-negative organisms, synergy with boronate was not observed or resulted in an enlargement of the inhibition zone ,5 mm with either cefotaxime or ceftazidime, except with two PER-1-producing strains that showed an enlargement of the ceftazidime inhibition of 6.6 and 7.8 mm, respectively (Table 1) . Using different cut-off values did not result in a greater ability to differentiate the phenotypes. We therefore suggest the adoption of a 5 mm cut-off value for enlargement of the inhibition zone with both cefotaxime and ceftazidime in the presence of boronate as a criterion for AmpC positivity.
The DSDT described in this work proved to be a simple and practical test to simultaneously detect production of ESBLs and AmpC-type b-lactamases with high sensitivity and specificity in P. mirabilis. Compared to the combo-disc test for detection of ESBLs according to the CLSI, the DSDT only needs two additional discs (CTX-BA and CAZ-BA), with minimal additional effort in terms of labour and costs, and is interpreted using the same criteria. It will be appropriate in the future to test the method with strains of P. mirabilis producing class A carbapenemase (KPC or GES) not available at the time of the study. Finally, analysis of recent clinical isolates of P. mirabilis showing reduced susceptibility to third-generation cephalosporins from our area revealed that a considerable proportion of them (70 %) was represented by AmpC producers. This finding underlines the emerging role that acquired AmpC-type enzymes can play in some settings as resistance determinants to expanded-spectrum cephalosporins in P. mirabilis. (2) (0) 8.9-9 (8.9) 5.3-6 (4.5) 0-1.6 (0.8) 0-1.2 (0.1) --CTX-M (2) (1) 12.6-13.6 (13.1) 1.8-3.4 (2.6) 20.7 to 1.3 (0.3) 1-1.6 (1.3) --PER-1 (2) (0) 5.7-11.9 (8.8) 12.2-13.8 (13) 2-3.8 (2.9) 6.6-7.8 (7.2) --Unknown (3) (3) 6.9-12.9 (9.4) 2-11.6 (6.9) 0-0.7 (0.4) 0-0.2 (0.6) --AmpC+ESBL (2) (1) 5.15-5.2 (5.1) 3-5.2 (4.1) 8.5-10.5 (9.5) 8-8.8 (8.4) 2 (100) 2 (100) Penicillinase (12) (12) 0-1 (0.08) 0-1.5 (0.13) 0 (0) 0 (0) 0 (0) 0 (0) Wild-type (12) (12) 0 ( Correspondence
